{"schema":"hottub-news/story/v1","story":"st_oypydhahltys5cmubzvq","title":"AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-oypydhahlt","count":1,"items":[{"id":"n_oypydhahltys5cmubzvq","seq":876584,"kind":"article","title":"AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026","url":"http://www.prnewswire.com/news-releases/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-analog-demonstrating-favorable-tolerability-and-pharmacokinetic-profile-at-easd-2026-302893611.html","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["health","business","economy","politics"],"authors":["AbbVie"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_oypydhahltys5cmubzvq","category":"science-technology","category_p":0.38999998569488525,"category2":"health","sentiment":"neutral","tone":-0.05000000074505806,"political":0.07000000029802322}]}